William Turner serves as Chief Regulatory Officer at Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing transformative therapies for patients with immunological kidney diseases, such as IgA nephropathy (IgAN). In this role, Turner leads the company's global regulatory strategy, overseeing interactions with regulatory agencies like the FDA and EMA to advance key pipeline assets, including the Phase 3 ORIGIN clinical trial of atacicept. His expertise ensures efficient regulatory pathways, from IND submissions to potential NDA filings, positioning Vera to deliver innovative treatments that address unmet medical needs. With over 30 years of experience in biopharmaceutical regulatory affairs, Turner has held senior leadership positions at leading companies. Prior to joining Vera in 2022, he was Senior Vice President and Global Head of Regulatory Affairs at BeiGene, where he directed regulatory strategies for oncology programs, securing multiple approvals including BTK inhibitors like Brukinsa. Previously, as Vice President of Global Regulatory Affairs at Pfizer's Oncology division, he contributed to the successful global launches of several blockbuster therapies, navigating complex regulatory landscapes across regions. Turner's achievements include spearheading over 50 INDs, NDAs, and MAAs, with a track record of accelerated approvals and Breakthrough Therapy Designations. A graduate of the University of California, San Diego, with advanced training in regulatory science, he is recognized for his strategic foresight and ability to bridge scientific innovation with regulatory compliance, making him a pivotal leader in Vera's mission to transform kidney disease care.